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INTRODUCTION
Parkinson’s disease (PD) is a multisystem disorder that is char-
acterized by a combination of various motor symptoms and 
nonmotor symptoms (NMS). The motor symptoms associat-
ed with PD are well known and are commonly treated by cli-
nicians.1-3 In contrast, recent studies of NMS have yielded 
mixed results despite these symptoms increasingly being rec-
ognized as an important part of PD symptoms and a signif-
icant cause of disability and, consequently, poor quality of 
life in PD patients.4-7 The various NMS in PD can be classi-
fied into four domains: neuropsychiatric, sensory, autonom-
ic, and sleep symptoms.8 Among these, rapid-eye-movement 
sleep behavior disorder (RBD), constipation, depression, and 
olfactory dysfunction appear during the premotor stages of 
PD and are often referred to as prodromal signs.4,7,9-11 How-
ever, other NMS such as cognitive impairment, genitouri-
nary dysfunction, gastrointestinal (GI) dysfunction, sleep 
disturbance, and visual hallucinations are associated with ad-
vancing age and disease severity.7 Accordingly, patients with 
advanced PD tend to have more severe NMS.6 The health-re-
lated quality of life (HrQoL) is considered critical in patients 
with neurodegenerative disorders, and recent PD research 
has increasingly focused on factors that affect HrQoL. HrQoL 
is closely associated with the severity of NMS,12-14 and NMS 
of PD are known to have a greater impact on HrQoL than do 
motor symptoms.6 Therefore, it is important to determine the 
NMS status of PD patients in large populations in order to 
better understand the impact of PD. 
In this Nonmotor symptoms And qualiTy of life In Par-
kinsON’s disease (NATION) study, we investigated NMS 
characteristics and their impact on HrQoL using a nationwide 
multicenter design. We aimed to determine the prevalence 
and severity of NMS according to the disease stage, status, 
and motor subtypes, and also the factors that influence each 
NMS domain and affect HrQoL. 
METHODS
Study design
The NATION study was a cross-sectional investigation that 
included data from 37 movement-disorders clinics widely 
distributed throughout South Korea. Principal investigators 
of participating clinics who were members of the Korean 
Movement Disorders Society (KMDS) were invited to take 
part in the study. Each clinic was confirmed to have the abili-
ty to implement the study protocol based on its previous 
participation in clinical studies. The study protocol was ap-
proved by the institutional review board of each institute, and 
all subjects were required to provide informed consent in 
compliance with the regulations of that board.
Subjects
The study included PD patients and healthy controls who 
were recruited between March 2012 and January 2013. PD 
was diagnosed based on the UK Parkinson’s Disease Society 
Brain Bank criteria, and patients were consecutively enrolled 
according to disease status as follows: 1) de novo group, any 
stage of PD with no prior anti-PD medications, 2) mild-to-
moderate group [modified Hoehn & Yahr (H&Y) stage of 
≤3] taking anti-PD medication, and 3) severe group (modi-
fied H&Y stage 4 or 5) taking anti-PD medication. To in-
crease the reliability of PD diagnosis, all PD patients were 
reassessed 6 months after the initial enrollment date. Normal 
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controls were recruited from volunteer caregivers of the pa-
tients at the inpatient and outpatient clinics who had no ev-
idence of neurological or serious medical illnesses in their 
medical history or a neurological examination. The follow-
ing exclusion criteria were applied: 1) history of systemic dis-
ease that might affect NMS or HrQoL (e.g., cancer or organ 
failure); 2) history of medication that might affect parkinson-
ism, NMS, or HrQoL; and 3) psychiatric illness or dementia 
[Mini Mental State Examination (MMSE) score of <20 points] 
restricting the understanding of the questionnaire.
Methods
We assessed the following demographic characteristics of the 
patients: sex, age, age at onset, duration of disease, marital 
state, occupation, and economic status. The modified H&Y 
stage and the Unified Parkinson’s Disease Rating Scale (UP-
DRS) were used to evaluate the overall severity of disease, in-
cluding motor disabilities.15,16 The clinical motor phenotype 
was classified according to Jancovic et al.17 The presence of 
motor complications (motor fluctuation and dyskinesia) was 
also assessed based on interviews and medical records. NMS 
were assessed based on the Korean version of the Nonmo-
tor Symptoms Scale (K-NMSS),18 Parkinson’s Disease Sleep 
Scale (PDSS), Beck Depression Scale (BDI), Beck Anxiety 
Inventory (BAI), and Parkinson Fatigue Scale (PFS). The Ko-
rean version of the MMSE (K-MMSE),19 the Korea version 
of the Montreal Cognitive Assessment (MoCA-K),20 and the 
Korean version of the Frontal Lobe Assessment Battery (K-
FAB)21 were used to evaluate cognitive function. The Korean 
version of the Neuropsychiatric Inventory Questionnaire (K-
NPI)22 was used to assessed behavioral and psychological 
symptoms. HrQoL was assessed using the Parkinson’s Dis-
ease Questionnaire-39 (PDQ-39).23 The motor phenotype was 
determined according to the UPDRS motor score. Each do-
main of the K-NMSS was used to assess the severity of NMS. 
Statistical analysis
The SPSS software package (version 15.0K for Windows, 
SPSS Inc., Chicago, IL, USA) was applied for all statistical 
evaluations. ANOVA was used for comparisons of groups 
conforming to normal distributions, while the Mann-Whit-
ney U and Kruskal-Wallis tests were used to compare vari-
ables that did not conform to a normal distribution. All com-
parisons between groups for each variable were carried out 
using Fisher’s exact test, and linear-by-linear associations 
were determined with Bonferroni’s post-hoc analysis. Spear-
man’s rank correlation coefficients were used to identify as-
sociations with other variables. Logistic regression analysis 
was used to assess the relative contributions of clinical vari-
ables to the total K-NMSS score. A difference was considered 
significant when the p value was <0.05. 
RESULTS
Demographic and clinical background information
In total, 323 PD patients [153 men, 170 women; age, 66.80± 
9.64 (mean±SD) years; median age, 69 years] and 94 healthy 
controls (33 men, 61 women; age, 62.96±9.39 years; medi-
an age, 64 years) were enrolled in the study. The demograph-
ic and clinical characteristics of the participants are presented 
in Supplementary Table 1 (in the online-only Data Supplement). 
The most common occupation was farming (n=286, 64.4%). 
The PD patients were divided into three subgroups: de novo 
PD (n=121), early PD (n=142), and advanced PD (n=60), 
in which the H&Y stages were 1.88±0.75, 2.05±0.61, and 
4.12±0.32, respectively. The PD patients were classified ac-
cording to motor phenotype into the 1) tremor-dominant 
(TD) group (n=27), 2) intermediate group (n=32), and 3) 
postural instability and gait disturbance (PIGD) group (n= 
264). As indicated in Supplementary Table 1 (in the online-
only Data Supplement), there were significant differences 
between PD patients and healthy control in scores on the 
PDSS, BDI, BAI, PFS, K-MMSE, MoCA-K, K-FAB, and K-
NPI. The PDSS scores did not differ significantly between 
the PD subgroups. The BDI scores indicated that the depres-
sion severity was significantly greater in the advanced PD 
group than in the de novo PD and early PD groups. Analy-
sis of the BAI scores indicated that anxiety was more severe 
in the advanced PD group than in the de novo PD group; 
however, the BAI score did not differ significantly between 
the de novo PD and early PD groups or between the early PD 
and advanced PD groups. The PFS score was higher in the 
advanced PD group than in the de novo PD group, but did 
not differ significantly between the de novo PD and early 
PD groups or between the early PD and advanced PD groups. 
Analysis of the K-MMSE scores indicated that global cog-
nitive dysfunction occurred more frequently in the advanced 
PD group than in the de novo PD and early PD groups, but 
that its prevalence did not differ significantly between the 
de novo PD and early PD groups. However, comparison of 
the MoCA-K and K-FAB scores showed significant differ-
ences only between the early PD and advanced PD groups. 
These results are summarized in Supplementary Table 2 (in 
the online-only Data Supplement).
NMS scale scores in the PD and control groups
The prevalence of NMS and mean scores on the K-NMSS 
in the PD and normal control groups are presented in Table 1. 
The prevalence of NMS was significantly higher in PD pa-
tients (98.1%) than in the control group (73.4%) for all K-
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NMSS domains. All of the K-NMSS domain scores were 
significantly higher in PD patients than in the normal con-
trols. The mean number of NMS in PD patients was 5.27 out 
of 12 domains. The mean number of affected K-NMSS do-
mains was higher in advanced PD patients (6.73) than in de 
novo PD patients (4.38) and early PD patients (5.40). The 
most common K-NMSS domains affecting PD patients were 
the sleep/fatigue (82%), mood/cognition problems (79.3%), 
attention/memory problems (77.4%), and urinary dysfunc-
tion (73.7%), with perception problems/hallucination (23.8%), 
weight change (25.4%), and excessive sweating (29.7%) be-
ing less frequent. In addition, compared with the control 
group, the PD patients showed higher prevalence ratios for 
perception problems/hallucination, weight change, pain, GI 
dysfunction, and taste/smell function, with PD-to-control 
ratios of 7.44, 5.91, 3.77, 3.15, and 3.04, respectively. The total 
score on the K-NMSS was higher (51.1±53.0) in the group 
with a higher PD onset age (>65 years, n=211) than in the 
group with an age at onset of <65 years (36.6±35.8). The for-
mer group also had higher scores in the dysautonomic do-
main, including (in descending order) cardiovascular, GI, 
and urinary dysfunctions, sleep/fatigue, and perception prob-
lems/hallucination.
NMS scale based on PD stage
The total number of affected K-NMSS domains increased 
with the PD stage. There were considerable differences in 
the total number of affected domains even in the de novo PD 
and control groups. Each K-NMSS domain score was signif-
icantly higher in the advanced PD group than in the de novo 
PD and early PD groups, with the exception of pain (Table 
2, Fig. 1).
Table 1. Prevalence and mean scores of NMSS domains between control and PD patients
NMSS domain
NMS prevalence NMSS score (mean±SD)
Controls (n=94),
number (%)
PD patients (n=323),
number (%)
Ratio prevalence
p-value
Controls PD patients
Ratio score
p-value
Cardiovascular (including falls) 30 (31.9) 152 (59.0)
1.85
0.003*
0.91±2.03 (0) 2.15±3.82 (0)
2.36
0.013*
Sleep/fatigue 55 (58.5) 262 (82.0)
1.40
<0.001*
2.70±3.74 (1) 7.89±9.66 (5)
2.92
<0.001*
Mood/cognition 46 (48.9) 253 (79.3)
1.62
0.001*
2.91±6.49 (0) 10.78±13.49 (6)
3.70
<0.001*
Perceptual/hallucinations 3 (3.2) 73 (23.8)
7.44
0.005*
0.04±0.25 (0) 1.46±4.86 (0)
36.5
<0.001*
Attention/memory 47 (50.0) 248 (77.4)
1.55
0.007*
2.10±3.42 (0.5) 4.97±6.27 (3)
2.37
<0.001*
Gastrointestinal 17 (18.1) 174 (57.0)
3.15
<0.001*
0.57±1.74 (0) 3.75±5.86 (1)
6.58
<0.001*
Urinary 41 (44.7) 234 (73.7)
1.65
0.002*
2.31±4.07 (0) 7.43±9.16 (4)
3.22
<0.001*
Sexual function 16 (17.0) 116 (36.2)
2.13
0.048*
1.57±4.83 (0) 2.77±6.00 (0)
1.76
<0.001*
Pains 7 (7.4) 84 (27.9)
3.77
<0.001*
0.18±0.75 (0) 1.33±2.82 (0)
7.39
<0.001*
Taste/smell function 10 (10.6) 100 (32.2)
3.04
<0.001*
0.22±0.78 (0) 1.49±2.87 (0)
6.77
<0.001*
Weight change 4 (4.3) 80 (25.4)
5.91
0.001*
0.09±0.48 (0) 0.81±2.12 (0)
9
<0.001*
Excessive sweating 9 (9.6) 93 (29.7)
3.09
<0.001*
0.22±0.84 (0) 1.24±2.66 (0)
5.64
<0.001*
Total 69 (73.4) 316 (98.1)
1.34
<0.001*
13.84±16.95 (8) 46.07±48.17 (33)
3.33
<0.001*
Ratio prevalence; PD patients:controls NMS prevalence ratio. Ratio score; PD patients:controls NMSS mean score ratio. NMSS score: data=mean±SD 
(median).
*Significant p<0.05, Wilcoxon rank sum test for median values. 
NMS: nonmotor symptoms, NMSS: non-motor symptom scale, PD: Parkinson’s disease.
www.thejcn.com  397
Kwon DY et al. JCN
NMS prevalence according to motor subtype
The prevalence of NMS and NMS domain scores according 
to motor subtype are presented in Table 3. Only the GI symp-
toms were more frequent in the PIGD than the TD subtype. 
Additionally, the GI score was the only symptom that was 
significantly worse in the PIGD than the TD subtype. Al-
though the scores in the other NMS domains tended to be 
worse in the PIGD subtype than in the TD subtype, the re-
sults were not statistically significant. The number of affect-
ed NMS domains did not differ significantly with the motor 
Fig. 1. Scores of domain (or items) of NMSS according to the subgroup of PD patients (de novo:early:advanced). CV: cardiovascular, GI: gastroin-
testinal, NMSS: non-motor symptom scale, PD: Parkinson’s disease.
Table 2. NMSS scores according to the subgroup of PD patients
De novo PD
(n=121)
Early PD 
(n=142)
Advanced PD 
(n=60)
p value† p value‡  p value§
Cardiovascular (including falls) 1.31±2.88 1.86±3.41 4.53±5.34 0.663 <0.001* <0.001*
Sleep/fatigue 5.71±7.60 6.89±7.49 14.60±11.53 0.780 <0.001* <0.001*
Mood/cognition 7.93±10.63 9.33±12.79 19.95±16.32 1.000 <0.001* <0.001*
Perceptual/hallucinations 0.33±1.16 1.21±3.64 4.58±9.04 0.519 <0.001* <0.001*
Attention/memory 3.77±4.64 4.67±6.34 8.08±7.86 0.713 <0.001* <0.001*
Gastrointestinal 2.42±3.93 3.13±4.93 7.90±8.72 0.926 <0.001* <0.001*
Urinary 5.34±7.26 6.91±8.55 12.85±11.70 0.451 <0.001* <0.001*
Sexual function 2.33±5.66 1.88±4.17 5.73±8.87 1.000 <0.001* <0.001*
Pains 1.30±2.91 1.04±2.32 2.03±3.57 1.000 0.071 0.294
Taste/smell function 0.77±2.04 1.35±2.53 3.23±4.12 0.272 <0.001* <0.001*
Weight change 0.65±1.92 0.53±1.44 1.82±3.32 1.000 <0.001* 0.001*
Excessive sweating 0.61±1.80 1.27±2.55 2.43±3.76 0.124 0.011* <0.001*
Total 35.51±31.96 40.00±40.19 87.75±67.01 0.506 <0.001* <0.001*
Data=mean±SD.
*Significant p<0.05, †Comparison between de novo and early PD, ‡Comparison between early PD and advanced PD, §Comparison between de novo and 
advanced PD.
NMSS: non-motor symptom scale, PD: Parkinson’s disease.
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PD subtype. 
NMS scale domain and association with clinical 
variables 
After adjusting for age, all K-NMSS domains were significant-
ly correlated with disease duration and all NMS, with the ex-
ception of the mood/cognition domain, which was corre-
lated with the total PD motor score (UPDRS part III score) 
and the total levodopa equivalent dosage (LED). However, 
after adjusting for disease duration, the total LED was not 
correlated with any of the K-NMSS domains (Supplementa-
ry Fig. 1 and Table 3 in the online-only Data Supplement). 
Table 4 presents the association between K-NMSS and each 
clinical variable based on multiple regression analysis. The 
disease duration and a depressive mood on BDI significantly 
affected all of the K-NMSS domains. Specific variables were 
significantly correlated in each domain: LED with sleep/fa-
tigue and sexual dysfunction; cognitive status on K-MMSE 
with cardiovascular symptoms; PDSS with attention/mem-
ory problems, perception problems/hallucination, and uri-
nary dysfunction; anxiety on BAI with attention/memory 
problems and excessive sweating; and fatigue on PFS with 
attention/memory problems, weight change, and taste and 
olfactory dysfunctions. 
NMS scale and HrQoL
The total K-NMSS scores were significantly correlated with 
HrQoL as assessed using a PD-specific questionnaire (PDQ-
39) (Fig. 2) (Supplementary Table 4 in the online-only Data 
Supplement). The sleep/fatigue and mood/cognition do-
mains in K-NMSS were the most important factors affect-
ing the HrQoL in PD subjects (rS=0.528 and rS=0.573, re-
spectively). In the PD subgroup analysis, sleep/fatigue and 
mood/cognition were the primary factors in the de novo 
and early PD groups. Attention/memory and mood/cogni-
tion were the most important factors for HrQoL in the ad-
vanced PD group, while miscellaneous variables and the 
sleep/fatigue domain were less likely to be correlated with 
HrQoL status. Finally, the perception problems/hallucina-
tion domain negatively impacted HrQoL in advanced PD 
but not in de novo or early PD. 
DISCUSSION
Our analysis of various aspects of the clinical presentation 
of NMS in PD has demonstrated that PD subjects show sig-
Table 3. NMS prevalence and scores according to the motor subtype of PD patients
NMS prevalence (%) NMS scores
PIGD
(n=264)
Intermed.
(n=32)
TD
(n=27)
p 
value†
PIGD
(n=264)
Intermediate
(n=32)
TD
(n=27)
p 
value†
Cardiovascular (including falls) 135 (48.9%) 16 (50%) 13 (48.1%) 0.989 2.26±3.78 2.53±3.98 2.26±4.88 0.932
Sleep/fatigue 229 (83%) 28 (87.5%) 19 (70.4%) 0.189 8.78±9.66 5.97±6.66 7.22±9.74 0.227
Mood/cognition 219 (79.3%) 26 (81.3%) 21 (77.8%) 0.946 11.82±14.5 9.53±10.71 9.93±13.04 0.582
Perceptual/hallucinations 70 (25.4%) 5 (15.6%) 6 (22.2%) 0.462 1.85±5.56 0.63±1.84 0.96±2.03 0.333
Attention/memory 220 (79.7%) 23 (71.9%) 18 (66.7%) 0.204 5.88±7.30 3.28±3.33 4.11±5.83 0.077
Gastrointestinal 171 (62.0%) 11 (34.4%) 9 (33.3%) <0.001* 4.45±6.23 2.38±4.83 2.07±5.62 0.040*
Urinary 210 (76.2%) 19 (59.4%) 20 (74.1%) 0.604 8.19±9.62 5.38±6.64 6.37±8.70 0.195
Sexual function 104 (37.7%) 12 (37.5%) 6 (22.2%) 0.579 3.31±6.43 2.23±5.13 1.03±3.19 0.194
Pains 83 (30.1%) 5 (15.6%) 6 (22.2%) 0.469 1.47±2.93 1.06±2.69 1.00±2.75 0.571
Taste/smell function 49 (32.3%) 13 (40.6%) 7 (25.9%) 0.783 1.46±2.81 1.97±2.81 1.85±3.77 0.549
Weight change 74 (26.8%) 6 (18.8%) 7 (25.9%) 0.890 0.89±2.16 0.78±2.51 1.07±2.77 0.880
Excessive sweating 84 (30.4%) 8 (25.0%) 8 (29.6%) 0.817 1.42±2.89 0.75±1.81 1.37±3.07 0.449
*p<0.05, †Statistical significances were tested by Two-by-K cross tabulation method (Pearson chi-square). 
NMSS: non-motor symptom scale, PIGD: postural instability and gait disturbance type, TD: tremor-dominant type.
400.00
300.00
200.00
100.00
0.00
PD
Q_
SI
0.00        50.00      100.00     150.00    200.00     250.00      300.00
NMSS_total
Fig. 2. Correlations between NMSS total score and PDQ39 SI (rS= 
0.329, p<0.001). NMSS: non-motor symptom scale, PDQ39: Parkin-
son’s Disease Questionnaire-39, PDQ39 SI: PDQ39 summary index.
rS=0.329, p<0.001
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nificant differences in the scores on mood, cognition, and 
sleep questionnaires compared with healthy controls. These 
findings suggest that PD is not simply a movement disor-
der, but instead is a systemic disorder that includes both mo-
tor symptoms and NMS, which would be due to the degen-
eration of nigrostriatal-extranigral systems.24,25 Although 
the importance of NMS in PD has been recognized recently, 
these symptoms have remained underreported by patients 
and overlooked by clinicians.5,26 Because NMS greatly impact 
the quality of life and can be a great burden for patients and 
their families,6,8,27 it is important to assess the complexity of 
NMS. The NMS of PD are heterogeneous and present with a 
Table 4. Association of each domain of non-motor symptoms scale with clinical variables by multiple regression analyses (disease duration, HYS, 
UPDRS 3, LED, MMSE, BDI, BAI, PAF)
NMSS domain Variables β±SE p value
Cardiovascular Disease duration
BDI
MMSE
0.007±0.004
0.113±0.021
-0.114±0.053
0.083
<0.001
0.032
Sleep/fatigue Disease duration
LED
BDI
0.037±0.008
-0.006±0.003
0.420±0.040
<0.001
0.059
<0.001
Mood/cognition Disease duration 
BDI
0.028±0.012
0.726±0.062
0.019
<0.001
Perceptual problems/hallucinations Disease duration
UPDRS 3
BDI
PFS
PDSS
0.012±0.005
0.040±0.020
0.135±0.028
-0.035±0.011
-0.029±0.007
0.020
0.049
<0.001
0.001
<0.001
Attention/memory Disease duration
BDI
BAI
PFS
PDSS
0.016±0.006
0.223±0.034
0.105±0.044
-0.032±0.016
-0.026±0.009
0.008
<0.001
0.017
0.050
0.003
Gastrointestinal Disease duration
BDI
PDSS
0.011±0.006
0.187±0.031
-0.014
0.080
<0.001
0.080
Urinary Disease duration 
BDI
PDSS
0.023±0.010
0.231±0.049
-0.049±0.012
0.021
<0.001
<0.001
Sexual function Disease duration
LED
BDI
MMSE
0.033±0.008
-0.002±0.001
0.119±0.034
0.165±0.088
<0.001
0.003
0.001
0.060
Miscellaneous_pain Disease duration
BDI 
0.005±0.003
0.051±0.016
0.084
0.001
Miscellaneous_taste or smell Disease duration
BDI
PFS
0.015±0.003
0.070±0.016
-0.011±0.006
<0.001
<0.001
0.096
Miscellaneous_weight change Disease duration
BDI
PFS
0.004±0.002
0.081±0.012
-0.010±0.005
0.057
<0.001
0.039
Miscellaneous_excessive sweating Disease duration
BDI
BAI
0.009±0.003
0.038±0.016
0.060±0.016
0.002
0.014
<0.001
BAI: Beck anxiety inventory, BDI: Beck depression inventory, MMSE: Mini Mental State Examination, NMSS: non-motor symptom scale, PDSS: Parkin-
son’s disease sleep scale, PFS: Parkinson fatigue scale.
400  J Clin Neurol 2016;12(4):393-402
Nonmotor Symptoms in Korean Parkinson’s Disease Patients JCN
variety of manifestations that can be classified in several 
ways, such as according to disease stage based on pathologi-
cal progression,28 according to symptomatic similarities, or 
according to major causative neurotransmitters.29-31 We iden-
tified tendencies of the NMS in the present study regardless 
of the specific underlying mechanism. The PD group showed 
both a higher prevalence and a higher score in all K-NMSS 
domains compared with the controls. Sleep/fatigue, mood/
cognition, attention/memory, and urinary dysfunctions were 
the most commonly reported NMS in PD patients. However, 
these domains were not specific to the study groups, being 
also prevalent in the control group, which indicates that the 
prevalence rates of NMS need to be interpreted cautiously 
in clinical practice. Our analysis of a prevalence ratio re-
vealed that the PD group exhibited a higher ratio for per-
ception problems/hallucination, miscellaneous symptoms 
(weight change, taste/smell, and pain), and GI dysfunction 
compared with the other domains, indicating that these do-
mains are more specific to PD. Accordingly, there were sev-
eral prevalent NMS that were correlated with the partici-
pants’ age, such as urinary and sleep symptoms, which were 
not specific to the PD patients. 
In our study, 98.1% of the PD patients showed at least one 
nonmotor symptom, and most commonly presented with 
sleep/fatigue issues, which is similar to the results of an Ital-
ian study.12 While urinary dysfunction was the fourth most 
common of the NMS in our study, several previous studies 
have found urinary dysfunction (nocturia or urgency) to be 
the most common NMS domain.5,6,32 In our survey, the 
prevalence of urinary dysfunction (73.7%) was not lower 
than in previous studies (54.5–68.4%),8,32,33 but the affective 
symptom scores in the baseline characteristics were high, 
although not compatible with a diagnosis of mood disorders, 
which can explain why sleep/fatigue and mood/cognition 
symptoms were more common than urinary dysfunction. 
This is similar to a previous study finding that more of the K-
NMSS domains were affected as the disease progressed.12 It 
is also compatible with research findings that NMS are in-
trinsic to PD but are also correlated with the involved struc-
tures and related to drugs taken as the disease progress-
es.7,24,34 We identified significant differences in the number 
and prevalence of involved NMS even in the de novo and ear-
ly stages of PD compared with controls. Meanwhile, there 
were no statistically significant differences in K-NMSS do-
mains in early PD stages and similar stages in the de novo PD 
group, which indicated that NMS in PD largely appear in 
later stages rather than being evenly distributed throughout 
the disease course.35 Previous investigations have found ob-
vious differences in clinical manifestations, prognosis, and 
drug responsiveness according to the PD motor pheno-
type.36,37 Although the pathophysiological basis is still un-
known, disparity in the patterns of dopaminergic cell loss, 
differences in other neurotransmitter systems, deposition 
of amyloid plaque, and brain atrophy have been proposed as 
explanations for differences in PD subtypes.38-41 In the pres-
ent study, the affected K-NMSS domains did not differ sig-
nificantly according to the PD phenotype between groups, 
with the exception of GI dysfunction. This contrasts with 
Khoo et al.42 reporting that even in early PD, a larger number 
of NMS were involved in the PIGD group. Another recent 
study found no significant difference in a larger PIGD and 
TD group comparison.43 In our study, there was a tenden-
cy—although not statistically significant—for the preva-
lence and number of affected NMS domains to both be 
higher in the PIGD subtype. However, there was a signifi-
cant difference in the numbers of PD phenotypes, in that 
82.3% of the recruited patients were of the PIGD subtype. 
When the results were adjusted for age, nearly all of the 
K-NMSS domains were correlated with disease duration, to-
tal LED, and motor status as assessed by UPDRS part III 
scores. However, after adjusting for the disease duration, the 
total LED was not correlated with any NMS. These results 
indicate that disease duration is more important than the 
LED to NMS in PD. The presentation of NMS varies, and 
patients present at various stages. Several NMS such as ol-
faction problems, RBD, constipation, and depression have 
been suggested to be preclinical features of neurodegenera-
tive diseases.8,10,11 In addition to these intrinsic features, ad-
ditional NMS can develop as the disease progresses, and 
these can significantly affect the patient’s condition.3,7,24,44 It 
is therefore possible that the disease duration contributes to 
the prevalence and severity of NMS.45-47 The NMS of PD can 
also be influenced by accompanying problems. Some NMS 
of PD are known to result from dopaminergic deficits, while 
other NMS do not respond to dopaminergic treatment.48 
Duration and depressive mood consistently affected all K-
NMSS domains, and each K-NMSS domain was influenced 
by specific clinical variables in the present study, as indicat-
ed in Table 4. 
Clinicians are primarily focused on motor symptoms, 
which may result in them overlooking NMS or HrQoL.49 How-
ever, NMS are a major determining factor of HrQoL in PD.13,32,50 
Gallagher et al.6 insisted that NMS can have a greater effect 
than motor features on some aspects of HrQoL in PD. Mood/ 
cognition and sleep/fatigue were the main factors associat-
ed with HrQoL in all of the PD subjects in the present survey. 
These results are similar to other studies finding that depres-
sion is a major detrimental factor for HrQoL in PD.14,51 The 
subgroup analysis indicated that the mood/cognition do-
main is a common factor that can determine HrQoL for the 
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overall PD group, but that sleep/fatigue contribute to de 
novo and early PD only, while the perception problems/hal-
lucination and attention/memory domains are specific for 
advanced PD. These observations suggest that the presenta-
tion of NMS differs according to disease stage, and that 
NMS attributed to HrQoL status are also influenced by dis-
ease stage. This result is comparable to a previous report of 
HrQoL associated with NMS varying according to the dis-
ease duration, and mood, sleep, fatigue, and autonomic symp-
toms negatively affecting NMS with regard to HrQoL in PD.6 
The burden experienced by PD patients is correlated with 
the number of NMS.27 Some NMS, such as depression, con-
stipation, and urinary and sleep dysfunctions, can be improved 
by the active treatment of parkinsonian features.8 According-
ly, HrQoL can also improve during NMS treatment.4,26,52 For 
these reasons, increasing the recognition of nonmotor aspects 
of PD is warranted for improving the HrQoL of affected sub-
jects, and tailored treatment strategies for diverse stages of 
PD should consider NMS. 
There were some limitations to this study. First, we did 
not analyze the presence of motor complications in the ad-
vanced PD group. Since motor complications in PD are sig-
nificantly associated with NMS,53 it is important to assess the 
effects of drug-related motor complications. However, we 
analyzed the correlations between the LED and K-NMSS do-
mains in order to elucidate the effects of this drug on NMS 
in PD. Second, most of the enrolled PD subjects were the 
PIGD type, which does not adequately represent the whole 
PD population; however, the PD phenotype analysis formed 
only a small part of our study, and the results are applicable 
to a large PD population. 
This was a multicenter, nationwide, representative study 
of Korean patients with a case-control comparison design. 
The diagnostic accuracy of the study was increased by recon-
firming the clinical diagnoses at 6 months after the initial 
diagnoses. Another strong point is that our nationwide Ko-
rean survey is one of the first large cross-sectional studies to 
elucidate the overall features and influences of nonmotor as-
pects of PD. The results from this study have highlighted the 
impact of NMS, which could allow the earlier detection of 
this degenerative disease, and thereby facilitate better thera-
peutic plans and improve the HrQoL of PD patients.
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